Introduction
Of the germ cell tumor patients failing standard firstline treatment, only 25% will benefit from currently established second-line treatment modalities by lasting remissions [1] . Depending on preceding prognostic variables [2] , most of them must be expected to progress even after high-dose carboplatin-based chemotherapy plus hematopoietic progenitor cell support (HDCT). Counseling patients on further treatment following HDCT is a demanding task: The patients are all young and heavily pretreated; the chances of remission with a useful quality of life are poor [2] ; but many want to go on with antitumor treatment.
Phase II trials in refractory patients following salvage therapy suggested daily oral etoposide [1, 3] and more recently paclitaxel [4] [5] [6] [7] to be useful treatment options in this patient population.
The benefits of chemotherapy for patients relapsing after HDCT has not been established to date. As this issue will become increasingly important, but prospective studies are unfeasible because of the expectedly small number of patients, a retrospective analysis was conducted.
Patients and methods

Data collection
Thirty centers in Austria, Germany and Switzerland likely to have germ cell tumor patients after HDCT on their follow-up programs were contacted in writing. Of the 20 replying centers, 10 had patients receiving post-HDCT chemotherapy for disease progression on their data files. Nine of them, i.e., six in Austria and three in Germany with a total number of 191 post-HDCT germ cell tumor patients, contributed data of 49 cases with post-HDCT chemotherapy. Data were collected with a standardized questionnaire. Items requested were patient identification, type and number of pre-HDCT cisplatin-based chemotherapy courses, date of HDCT and post-HDCT response evaluation, site of post-HDCT disease progression; time, type, dosage and number of post-HDCT chemotherapies including response evaluation; factors prompting discontinuation of chemotherapeutic modalities; condition at last follow-up or date and cause of death. The completed questionnaires were checked for plausibility, completeness and consistency of the data by J.P., but no further checks, i.e., laboratory studies, histology or radiology reviews, or other source data verification, were performed. Only patients with complete data sets were included in the analysis. Data were entered in a personal computer and data entry was checked by J.P. and F.S.
Definitions
Complete remission (CR) was defined as clinical CR (= total disappearance of the tumor by all radiological studies as well as normalization of human chorionic gonadotropin (HCG) and alfa-fetoprotein (AFP) levels with chemotherapy alone or pathologic CR (= complete resection of non-viable malignancy or of mature teratoma without any evidence of residual disease).
Marker-negative partial remission (PRm-) was defined as reduction of any radiologically measurable disease and normal HCG and AFP levels.
Marker-positive partial remission (PRm+) was defined as reduction of any radiologically measurable disease by greater than 50%, but elevated HCG and /or AFP levels or a greater than 90% reduction of elevated tumor markers.
Progressive disease (PD) was defined as increase of any radiologically measurable tumor mass by greater than 25% or a greater than 10% increase in elevated tumor markers.
No change (NC) was defined as response neither qualifying as PRm-nor as PRm+ or PD.
Response was defined as CR, PRm-or PRm+.
No response was defined as NC or PD. Before the response to any chemotherapeutic modality was evaluated, patients had to have completed at least one full chemotherapy course with a survival time of 4 weeks or more.
High-dose chemotherapy. Patients evaluated in this study had received HDCT with either carboplatin + etoposide + ifosfamide (CEI) [8] , carboplatin + etoposide + cyclophosphamide (CEC) [9] or cisplatin + etoposide + ifosfamide (HD-PEI) [10] with hematopoietic progenitor or stem cell support per protocol as described in [8] [9] [10] .
Interval was defined as the time in weeks between the (last) HDCT and the next post-HDCT chemotherapy.
Survival was defined as the survival time in weeks counted from the beginning of post-HDCT chemotherapy.
Patients
Inclusion criteria. Patients with germ cell tumors were eligible, if they had undergone systemic post-HDCT chemotherapy for disease progression and if a complete set of the data requested in the questionnaire was available for them.
Of the 49 patients, two were excluded: In one post-HDCT chemotherapy had been administered locally (intrathecally) rather than systemically, while the other one was lost to follow-up so that survival was not evaluable. This left a total of 47 evaluable cases. All of them had non-seminomatous germ cell cancers.
Detailed patient data are shown in Table 1 .
Data analysis and statistics
As preceding variables (site of primary tumor, number of pre-HDCT chemotherapy courses, HDCT regimen, response to HDCT, interval between HDCT and post-HDCT treatment, metastasizing pattern) may have been more important for the treatment outcome in these heavily pretreated patients than the type of post-HDCT chemotherapy, these were also correlated with response and survival. Correlating the different chemotherapy regimens applied with response and survival did not appear to be useful for various reasons: Patients included in this retrospective study received a variety of post-HDCT chemotherapy regimens (Table 2) ; up to six different regimens with a variable number of treatment courses were administered; the time to response varied (first to third chemotherapy regimens); the doses applied differed; and the number of patients was small. To assess the efficacy of the cytostatic drugs used patients were, therefore, allocated to two groups, i.e., those receiving a single drug or drug combination and those who did not. The resultant paired groups were subjected to univariate and multivariate analysis and compared for the best response to post-HDCT chemotherapy and for survival time.
Response was analyzed by the chi-square test and by Fischer's exact test. For survival curves the Kaplan-Meier plot and the log-rank test were used [11] . Multivariate survival analysis was done with Cox's proportional hazards regression model [12] .
P values of less than 0.05 were considered to indicate statistical significance.
Results
Of the 191 germ cell tumor patients who had received HDCT in the nine participating centers, 48 (25%) underwent systemic post-HDCT chemotherapy for disease progression.
The 47 evaluable patients received one to six different chemotherapy regimens (median, two regimens) with one to nine courses (median, two courses). In only two patients treatment was discontinued because of drug toxicity; in all others disease progression prompted drug withdrawal or replacement by another regimen. Abbreviations: HDCT -high-dose chemotherapy; CEC -carboplatin + etoposide + cyclophosphamide [9] ; CEI -carboplatin + etoposide + ifosfamide [8] ; HD-PEI -high-dose cisplatin + etoposide + ifosfamide [10] ; CR -complete remission; PRm--marker-negative partial remission; PRm+ -marker-positive partial remission, NC -no change; PD -progressive disease. 
Response
In 17 of the 47 patients (36%) post-HDCT chemotherapy achieved remissions: These were CR in four patients, PRm-in four patients and PRm+ in nine patients. Of the 17 responders, 10 responded to the first post-HDCT regimen, while seven did not, but were found to show objective evidence of a response to the second or third regimens.
The correlation of the best response to post-HDCT chemotherapy with preceding variables (primary tumor, pre-HDCT chemotherapy courses, HDCT regimen, response to HDCT, interval between HDCT and post-HDCT chemotherapy, metastasizing pattern) is shown in Table 3 . Of all these variables, only the interval between HDCT and post-HDCT chemotherapy for disease progression was significantly correlated with remissions: Post-HDCT chemotherapy within three months of completing HDCT achieved remissions in no more than one of 16 patients. By contrast, retreatment after more than one year was associated with a remission rate of four in six cases.
The chemotherapy regimens used and the responses to them are shown in Table 2 . As explained in 'Patients and methods', the great variety of chemotherapy regimens applied in this retrospective analysis necessitated patient grouping for a statistical analysis of the efficacy of chemotherapy: patients receiving a given drug or drug combination were compared with those not receiving Abbreviations: HDCT -high-dose chemotherapy; CEC -carboplatin, etoposide, cyclophosphamide [9] , CEI -carboplatin, etoposide, ifosfamide [8] ; HD-PEI -high-dose cisplatin, etoposide, ifosfamide [10] . the drug or drug combination for the best response achieved. The pertinent data are shown in Table 4 . Of the single drugs evaluated, only ifosfamide reached statistical significance. Among the drug combinations, cisplatin + etoposide, cisplatin + ifosfamide and cisplatin + etoposide + ifosfamide were significantly correlated with response. Paclitaxel in combination with ifosfamide and /or cisplatin showed the highest significance.
Survival
The median Kaplan-Meier survival estimates of the 47 patients evaluated in this study was 26 weeks. At the time of data analysis seven patients were still alive at 13 to 103 weeks. Of these, two had progressive disease, four were in marker-positive partial remission (PRm+) and one in sustained complete remission without any treatment for 22 months at the time this manuscript was written.
Patients responding to post-HDCT chemotherapy for disease progression had a highly significant survival benefit with a projected median survival of 65 weeks in responders and of 13 weeks in non-responders (log-rank 18.93, P = 0.00001).
Of the preceding variables evaluated by univariate analysis (Table 5) , only the interval between HDCT and post-HDCT chemotherapy reached statistical significance. Like the correlation of the response with the Abbreviations: HDCT -high-dose chemotherapy; CEC -carboplatin, etoposide, cyclophosphamide [9] ; CEI -carboplatin, etoposide, ifosfamide [8] ; HD-PEI -high-dose cisplatin, etoposide, ifosfamide [10] .
preceding variables, the survival in patients needing post-HDCT chemotherapy less than three months after HDCT was particularly poor. Table 6 shows the survival data obtained by univariate analysis for patients receiving a given cytostatic drug or drug combination and for those who did not. Of the single drugs applied, cisplatin, paclitaxel and ifosfamide correlated significantly with survival, while daily oral etoposide did not. Among the drug combinations, only paclitaxel combined with ifosfamide or cisplatin reached significance.
Of all the factors potentially affecting survival, i.e., preceding variables and cytostatic drugs used, only treatment with paclitaxel and ifosfamide retained independent prognostic significance (P = 0.0008 and 0.0063, respectively) on multivariate analysis. While prognostically significant for survival on univariate analysis, the interval failed to retain independent prognostic significance on multivariate analysis.
Discussion
Most patients with metastatic germ cell tumors who relapse after first-line therapy or achieve incomplete responses show disease progression after conventionaldose salvage chemotherapy [1] and HDCT, the only curative third-line approach which is considered state-of-the-art for testicular germ cell tumors responding incompletely to first-line treatment [13] . If they are ineligible for surgical salvage [14] or palliative radiotherapy, the last resort for them would be to resume cytostatic chemotherapy.
The primary objective of our survey was to find out how many patients undergo post-HDCT chemotherapy and how many of them appear to benefit from it in order to see whether post-HDCT chemotherapy makes any sense at all in this population.
We found that post-HDCT chemotherapy was administered to no less than one quarter of all patients in the participating centers. In light of the post-HDCT relapse rate of more than 70% [2] , this is about one third of all patients relapsing after HDCT. As the other two-thirds are apparently no longer willing or able to undergo chemotherapy, this represents a positive selection.
The other objective of our study was to identify prognostic outcome variables for post-HDCT chemotherapy. For the outcome of HDCT progressive disease before HDCT, mediastinal primary tumor, refractory disease to conventional-dose cisplatin and (3-HCG > 1,000 U/l were defined as prognostic variables [2] .
In our study the response to the previous high-dose chemotherapy and the site of the primary tumor did not have prognostic significance for the outcome of post-HDCT chemotherapy. Tumor markers before post-HDCT chemotherapy were not included in our analysis. On univariate analysis only the interval between HDCT and post-HDCT chemotherapy, which probably is equivalent to progression-free survival, correlated significantly with both response and survival. This agrees well with the clinical experience available. The benefits are poorest for patients who need post-HDCT chemotherapy within no less than three months after HDCT. Unlike the use of ifosfamide and paclitaxel for post-HDCT chemotherapy, the interval did, however, not retain independent prognostic significance on multivariate analysis of the prognostic factors for survival.
Of the many cytostatic drugs tested in cisplatinrefractory patients, only etoposide [17] , ifosfamide [18] and paclitaxel [19] showed useful antitumor activity. The efficacy of these drugs in refractory patients who had previously undergone HDCT is still poorly understood. What little evidence is available was derived from studies in cisplatin-refractory patients who rarely had been given prior HDCT.
Miller and Einhorn [3] and Greco et al. [15] reported 10 patients who had received daily oral etoposide for disease progression after HDCT. Of these, three responded and complete remission was sustained for three years in one of them.
In phase II studies of paclitaxel in cisplatin-refractory patients Bokemeyer et al. [6] and Gerl et al. [16] found three of 13 patients with disease progression after HDCT to respond, while Motzer et al. [4] did not observe any response in any one of the five patients treated with post-HDCT paclitaxel. To the best of our knowledge data on post-HDCT ifosfamide treatment are not available.
The response rate to daily oral etoposide was four in 19 cases in our study. This agrees fairly well with reported rates for cisplatin-refractory patients [1, 3, 15] . Daily oral etoposide is widely used in these patients because of its relatively good tolerance and its suitability for out-patient treatment. However, daily oral etoposide did not show any prognostic significance for both response and survival in our study.
Single-drug treatment with paclitaxel produced a response in no more than four of 24 patients. Adding up the figures for all combinations of paclitaxel with other cytostatic drugs increased the response rate to eight in 29 cases. For the combined use of paclitaxel with ifosfamide and /or cisplatin the response rate was four in five cases. As a result, the use of this combination was found to be a significant prognostic factor for response. Paclitaxel in this combination was also shown to have significance for survival. On multivariate analysis paclitaxel was retained as one of two independent prognostic factors for survival. The only patient in sustained pathologic complete remission after post-HDCT chemotherapy had received eight courses of paclitaxel + cisplatin at a dose of 175/75 mg/m 2 . At the time this manuscript was submitted he had been in remission for 30 months counted from the beginning of post-HDCT chemotherapy and for 24 months after completing treatment.
These data appear to be related to the observation that paclitaxel may reverse acquired cisplatin resistance of germ cell tumors [5] , as was shown in in vitro studies [20] . It suggests once more that phase II and phase III trials with paclitaxel combinations are justified in poorrisk germ cell cancer patients [6, 21] .
While correlated with survival on univariate analysis, the use of cisplatin for post-HDCT chemotherapy did not retain independent prognostic significance on multivariate analysis.
Although ifosfamide had already been administered for HDCT in more than half of our patients, its use for post-HDCT chemotherapy was still significantly correlated with response and survival both on univariate and multivariate analysis. The composition of the preceding HDCT regimen did not show any statistically significant correlation with the outcome of post-HDCT chemotherapy. Our data do not show whether ifosfamide is only active in combination with cisplatin and/or paclitaxel or also as a single agent, because it was only administered in combination regimens to the patients in our study.
The demands made on the heavily pretreated patients by resuming chemotherapy should be carefully weighed against what little chances they have for tumor control. Therefore, the likely benefits of another chemotherapy must be assessed in light of the performance status, expected toxicity and the cumulative toxicity to which the patients had been exposed in the past. The retrospective design of our study ruled out a reliable assessment of the performance status and an analysis of toxicities. But it was remarkable to see that drug toxicity was only recorded twice as the factor prompting discontinuation of treatment. The cause of death in all nonsurvivors was the underlying germ cell tumor. Drugrelated deaths were not documented.
With all due reservations befitting a retrospective study we conclude that one third of the patients who are still eligible for post-HDCT chemotherapy because of disease progression after HDCTwill benefit by remission and prolonged survival. This benefit is all the more likely to occur the longer the interval between HDCT and post-HDCT chemotherapy. Paclitaxel and ifosfamide combined with each other and with cisplatin turned out to be the most effective drugs.
